STS has a small molecular weight and a serum half-life of 15 min in patients with normal renal function, but the exact mechanism of action of STS in HD patients remains poorly understood, which makes the standardization and management of STS therapy challenging [41]. The gene discussed is STS; the disease is Huntington disease.